SPK1/S1P axis confers gastrointestinal stromal tumors (GISTs) resistance of imatinib

BACKGROUND: Imatinib mesylate (IM) is highly effective in the treatment of gastrointestinal stromal tumors (GISTs). However, the most of GISTs patients develop secondary drug resistance after 1–3 years of IM treatment. The aim of this study was to explore the IM-resistance mechanism via the multi-sc...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yan, Zhang, Rui, Mi, Dandan, Wang, Qiuju, Huang, Tingwenli, Dong, Xinwei, Zhang, Hongwei, Xiao, Hongtao, Shi, Sanjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398498/
https://www.ncbi.nlm.nih.gov/pubmed/35999321
http://dx.doi.org/10.1007/s10120-022-01332-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398498/
https://www.ncbi.nlm.nih.gov/pubmed/35999321
http://dx.doi.org/10.1007/s10120-022-01332-7

Ejemplares similares